Ambient Biosciences’ (formerly Upkara) seeks partnerships for breakthrough biomolecule stabilization technology under leadership of new CEO
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of work with VAR2 Pharmaceuticals on the production of the company’s two antibody candidates targeting cancer-specific carbohydrate structures for cancer treatment.
AGC Biologics Announces Successful Completion of Production of Cancer-Specific Therapeutic Antibody Fragments with Var2 Pharmaceuticals
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of work with VAR2 Pharmaceuticals on the production of the company’s two antibody candidates targeting cancer-specific carbohydrate structures for cancer treatment.
TwinStrand Biosciences Initiates Regulatory Approval Process for Duplex Sequencing Mutagenesis Assays with OECD
SEATTLE, April 24, 2024 /PRNewswire/ — TwinStrand Biosciences®, the pioneer in Duplex Sequencing technology, which delivers accurate insights to researchers in applications ranging from genetic toxicology to residual cancer detection announces the successful acceptance of the standard project submission form (SPSF) by the Organization for Economic Cooperation and Development (OECD). This significant milestone will accelerate commencement of the global regulatory acceptance process for error-corrected Next Generation Sequencing (ecNGS) for mutagenesis testing.
Nodexus Adds Flow Cytometry Leaders to Scientific Advisory Board
SAN JOSE, Calif.–(BUSINESS WIRE)–Nodexus Inc., a leader in automated benchtop single-cell characterization and microfluidic isolation technologies, today announced that three leading experts in cytometry sciences, pathology, and cancer biology have joined its Scientific Advisory Board (SAB). The Nodexus SAB is chaired by Professor Jonni Moore, PhD, one of the world’s leading experts in flow cytometry, laboratory medicine, and cellular immunology.
Ultivue Announces its STARVUE™ Image Data Science Platform, Providing Researchers with an Integrated, AI-Driven Analytical Solution for Generating Spatial Insights
CAMBRIDGE, Mass., April 3, 2024 /PRNewswire/ — Ultivue, a market leader in quantitative proteomic biomarker detection and advanced spatial tissue profiling, is unveiling its spatial insights platform, STARVUE™, at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 5-10 in San Diego, CA. STARVUE™ is the culmination of Ultivue’s multi-year engineering efforts to bring the latest innovations in artificial intelligence and image data science to translational and clinical research applications, via a highly accurate and scalable analytical solution.
Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
SECAUCUS, N.J., April 2, 2024 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome sequencing (WGS), today announced a research collaboration designed to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
AGC Biologics to Manufacture First-ever FDA Approved Gene Therapy for Early-onset MLD, Orchard Therapeutics’ Lenmeldy™
Today, we announced that the U.S. Food and Drug Administration (FDA) has cleared our Milan site to begin commercial manufacturing for the lentiviral vector and genetically modified cell drug product (DP) of Orchard Therapeutics’ Lenmeldy™ (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy for the treatment of pre-symptomatic late infantile, pre-symptomatic early juvenile and early symptomatic early juvenile metachromatic leukodystrophy (MLD). Lenmeldy received approval by the FDA on Monday, March 18.
MBrace Therapeutics Appoints Steve Alley as Chief Scientific Officer
SAN DIEGO (March 5, 2024) – MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of patients with cancer by developing novel antibody-drug conjugates (ADCs), today announced the appointment of Steve Alley, Ph.D., as chief scientific officer. Dr. Alley joins MBrace with over 20 years of experience at Seagen, a world-leader in ADCs that was acquired by Pfizer in 2023.
Inoviv Launches NeuroKey-3™, A Quantitative Multiplexed IP-MS Assay to Measure Key Low-Level Markers in Neurodegeneration
LONDON, March 1, 2024 /PRNewswire/ — Biomarker pioneer, Inoviv, announces the launch of its proprietary NeuroKey-3™ assay, an end-to-end service offering to measure key low-level markers in neurodegeneration in human plasma. The launch of NeuroKey-3™ signifies an important milestone in Inoviv’s mission to generate novel molecular insights that transform drug development and healthcare globally. Inoviv will […]
Inoviv Secures Investment to Expand Quantitative Proteomics Product Offerings to Accelerate Drug Development Pipelines
LONDON–(BUSINESS WIRE)–Biomarker pioneer Inoviv has secured significant funding from venture capital firm Hoxton Ventures and leading investment manager Foresight Group to expand the delivery of highly accurate, fully quantitative targeted biomarker workflows and panels. Building on previous funding from Hoxton Ventures, this latest investment will enable Inoviv to further expand its commercial activities to support […]
